Cencora Inc. (COR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cencora Inc. (COR) has a cash flow conversion efficiency ratio of -1.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.31 Billion) by net assets ($2.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cencora Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Cencora Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cencora Inc. total liabilities for a breakdown of total debt and financial obligations.
Cencora Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cencora Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AutoZone Inc
NYSE:AZO
|
-0.292x |
|
Larsen & Toubro Limited
IL:LTOD
|
N/A |
|
Larsen & Toubro Limited
NSE:LT
|
0.076x |
|
Airbnb Inc
NASDAQ:ABNB
|
0.064x |
|
Wesfarmers Ltd
AU:WES
|
0.317x |
|
Lloyds Banking Group plc
F:LLD2
|
N/A |
|
Realty Income Corporation
NYSE:O
|
0.024x |
|
Aflac Incorporated
NYSE:AFL
|
0.042x |
Annual Cash Flow Conversion Efficiency for Cencora Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Cencora Inc. from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Cencora Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.51 Billion | $3.88 Billion | 2.570x | -52.37% |
| 2024-09-30 | $645.94 Million | $3.48 Billion | 5.395x | -28.00% |
| 2023-09-30 | $522.00 Million | $3.91 Billion | 7.493x | -80.24% |
| 2022-09-30 | $71.27 Million | $2.70 Billion | 37.926x | +731.19% |
| 2021-09-30 | $584.41 Million | $2.67 Billion | 4.563x | +310.65% |
| 2020-09-30 | $-1.02 Billion | $2.21 Billion | -2.166x | -376.59% |
| 2019-09-30 | $2.99 Billion | $2.34 Billion | 0.783x | +69.23% |
| 2018-09-30 | $3.05 Billion | $1.41 Billion | 0.463x | -34.29% |
| 2017-09-30 | $2.11 Billion | $1.49 Billion | 0.704x | -52.82% |
| 2016-09-30 | $2.13 Billion | $3.18 Billion | 1.493x | -75.88% |
| 2015-09-30 | $633.52 Million | $3.92 Billion | 6.188x | +727.65% |
| 2014-09-30 | $1.96 Billion | $1.46 Billion | 0.748x | +120.07% |
| 2013-09-30 | $2.32 Billion | $788.12 Million | 0.340x | -36.06% |
| 2012-09-30 | $2.46 Billion | $1.31 Billion | 0.531x | +30.43% |
| 2011-09-30 | $2.87 Billion | $1.17 Billion | 0.407x | +8.56% |
| 2010-09-30 | $2.95 Billion | $1.11 Billion | 0.375x | +30.06% |
| 2009-09-30 | $2.72 Billion | $783.76 Million | 0.289x | +6.08% |
| 2008-09-30 | $2.71 Billion | $737.07 Million | 0.272x | -30.21% |
| 2007-09-30 | $3.10 Billion | $1.21 Billion | 0.390x | +99.90% |
| 2006-09-30 | $4.14 Billion | $807.26 Million | 0.195x | -45.34% |
| 2005-09-30 | $4.28 Billion | $1.53 Billion | 0.357x | +87.57% |
| 2004-09-30 | $4.34 Billion | $825.08 Million | 0.190x | +114.65% |
| 2003-09-30 | $4.01 Billion | $354.81 Million | 0.089x | -45.18% |
| 2002-09-30 | $3.32 Billion | $535.93 Million | 0.162x | +1246.68% |
| 2001-09-30 | $2.84 Billion | $-40.00 Million | -0.014x | -101.84% |
| 2000-09-30 | $282.29 Million | $216.58 Million | 0.767x | +4152.92% |
| 1999-09-30 | $166.30 Million | $3.00 Million | 0.018x | -98.92% |
| 1998-09-30 | $75.30 Million | $125.90 Million | 1.672x | +357.09% |
| 1997-09-30 | $14.30 Million | $-9.30 Million | -0.650x | +40.17% |
| 1996-09-30 | $-36.80 Million | $40.00 Million | -1.087x | -514.33% |
| 1995-09-30 | $-135.70 Million | $-35.60 Million | 0.262x | +193.91% |
| 1994-09-30 | $-300.70 Million | $84.00 Million | -0.279x | -- |
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order … Read more